Reported Standalone quarterly numbers for Suven Pharmaceuticals are:Net Sales at Rs 259.16 crore in March 2021 up 40.27% from Rs. 184.76 crore in March 2020.
Quarterly Net Profit at Rs. 64.45 crore in March 2021 up 21.06% from Rs. 53.24 crore in March 2020.
EBITDA stands at Rs. 96.99 crore in March 2021 up 17.29% from Rs. 82.69 crore in March 2020.
Suven Pharma EPS has decreased to Rs. 2.53 in March 2021 from Rs. 4.18 in March 2020.
Suven Pharma shares closed at 480.45 on June 10, 2021 (NSE)
| Suven Pharmaceuticals | | Standalone Quarterly Results | in Rs. Cr. |
|
| Mar'21 | Dec'20 | Mar'20 | | Net Sales/Income from operations | 259.16 | 274.93 | 184.76 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 259.16 | 274.93 | 184.76 | | EXPENDITURE | | Consumption of Raw Materials | 87.37 | 79.76 | 64.24 | | Purchase of Traded Goods | -- | -- | -- | | Increase/Decrease in Stocks | 3.98 | -13.55 | -11.27 | | Power & Fuel | -- | -- | -- | | Employees Cost | 16.51 | 21.35 | 19.52 | | Depreciation | 8.31 | 8.76 | 7.05 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | 1.51 | 2.66 | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 56.10 | 46.56 | 34.92 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | 85.38 | 129.40 | 70.30 | | Other Income | 3.30 | 4.84 | 5.34 | | P/L Before Int., Excpt. Items & Tax | 88.68 | 134.24 | 75.64 | | Interest | 1.87 | 2.73 | 7.20 | | P/L Before Exceptional Items & Tax | 86.81 | 131.51 | 68.44 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | 86.81 | 131.51 | 68.44 | | Tax | 22.35 | 33.87 | 15.20 | | P/L After Tax from Ordinary Activities | 64.45 | 97.63 | 53.24 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | 64.45 | 97.63 | 53.24 | | Equity Share Capital | 25.46 | 25.46 | 12.73 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | 2.53 | 3.84 | 4.18 | | Diluted EPS | 2.53 | 3.84 | 4.18 | | EPS After Extra Ordinary | | Basic EPS | 2.53 | 3.84 | 4.18 | | Diluted EPS | 2.53 | 3.84 | 4.18 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|